Cardiovascular considerations in patients treated with HIV protease inhibitors.
Highly active antiretroviral therapy (HAART) has dramatically reduced mortality from HIV infection, transforming it in many cases to a chronic condition. However, protease inhibitors (PIs), which are integral components of most HAART regimens, are commonly associated with a host of metabolic disturbances that may increase the risk of cardiovascular disease in patients with HIV infection, potentially counteracting some of the positive health effects of PIs. Dyslipidemia is of particular concern. The Adult AIDS Clinical Trials Group has established preliminary guidelines to evaluate and treat PI-associated dyslipidemia. A number of strategies exist for the management of PI-based dyslipidemia in HAART recipients; their advantages and disadvantages should be considered when treating patients with HIV infection.
Colagreco
Joseph P
JP
Division of Nursing, Steinhardt School of Education, New York University, USA.
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods / Q000451:nursing; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000628:therapy*; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000600:supply & distribution; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000139:chemically induced; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D024802:Nurse's Role; D010347:Patient Care Planning; D012307:Risk Factors
D017320:HIV Protease Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents